Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7206MR)

This product GTTS-WQ7206MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7206MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3710MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ1555MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ11664MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ3566MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ6772MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ1724MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ2663MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ8648MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW